Show simple item record

dc.contributor.authorMicha, A
dc.contributor.authorParvaiz, MA
dc.contributor.authorO'Riordan, L
dc.contributor.authorMacNeill, F
dc.contributor.authorRusby, JE
dc.date.accessioned2022-05-04T14:10:59Z
dc.date.available2022-05-04T14:10:59Z
dc.identifier.citationClinical breast cancer, 2022en
dc.identifier.issn1526-8209
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/5112
dc.identifier.eissn1938-0666en_US
dc.identifier.eissn1938-0666
dc.identifier.doi10.1016/j.clbc.2022.02.012en_US
dc.identifier.doi10.1016/j.clbc.2022.02.012
dc.description.abstract<h4>Aims</h4>Isotope and blue dye dual localization in sentinel lymph node biopsy (SLNB) gives localization rates of over 98% and is the recommended technique. However blue dye risks a range of adverse reactions. Since 2010, for clinically node negative disease, we have only used blue dye if there is no clear isotope signal at surgery.<h4>Methods</h4>Electronic records of patients who underwent isotope-only SLN localization between July 2010 and April 2012 were examined. Data were collected on localization and oncological outcomes.<h4>Results</h4>426 patients were included. Isotope-only localization rate was 97.4% (415/426). The median follow-up was 63.5 months (IQR: 60.7-70.9). Median age was 57 (IQR: 48-67). Median SLN yield was 2 (range: 1-5). Axillary recurrence rate was 1.4% with median time to recurrence of 39.3 months. In-breast recurrence, distant disease and contralateral breast cancer rates were 2.8%, 7%, and 1.9% respectively and 15 (3.5%) patients died of metastatic breast cancer.<h4>Conclusion</h4>Isotope-only SLNB has a comparable localization rate to dual isotope/blue dye SLNB and can spare the risk of blue dye adverse reactions. The low axillary recurrence rate, maintained to more than 5 years, confirms that isotope-only SLNB is a feasible and safe alternative to dual blue dye/isotope localization.en_US
dc.formatPrint-Electronicen_US
dc.languageengen_US
dc.language.isoengen
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/en
dc.titleIsotope-Only Localization for Sentinel Lymph Node Biopsy - Medium-Term Oncological Outcomes.en
dc.typeJournal Article
dcterms.dateAccepted2022-02-25
rioxxterms.versionVoRen
rioxxterms.versionofrecord10.1016/j.clbc.2022.02.012en
dc.relation.isPartOfClinical breast canceren_US
pubs.notesNot knownen_US
pubs.organisational-group/ICR
pubs.publication-statusPublisheden_US
pubs.embargo.termsNot knownen_US
dc.contributor.icrauthorRusby, Jenniferen_US


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record

http://creativecommons.org/licenses/by/4.0/
Except where otherwise noted, this item's license is described as http://creativecommons.org/licenses/by/4.0/